Article Dans Une Revue Clinics and Research in Hepatology and Gastroenterology Année : 2023

Acute liver failure following immune checkpoint inhibitors

Résumé

We report the case of a 64-year-old man admitted to intensive care unit for liver failure secondary to immune-mediated hepatitis. This patient suffered from a progressing laryngeal squamous cell carcinoma. A treatment was started with immune checkpoint inhibitors combining anti PD-L1 plus novel anti-TIGIT or placebo (ATEZOLIZUMAB plus TIRAGOLUMAB or placebo), as part of a clinical trial. The patient then developed immune-mediated hepatitis, proven by liver biopsy. Despite 14 days of corticosteroids at 2 mg/kg the condition of the patient worsened, with the development of liver failure. The patient was admitted to intensive care unit, treated with plasma exchange, and made a complete recovery from this life-threatening condition. To our knowledge this is the case of a successful use of plasma exchange to treat ATEZOLIZUMAB +/- TIRAGOLUMAB induced liver toxicity.

Fichier principal
Vignette du fichier
2023 Renault et al., Acute liver failure.pdf (236.54 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

hal-04205722 , version 1 (17-09-2023)

Licence

Identifiants

Citer

Thomas Renault, Lucy Meunier, Clément Monet. Acute liver failure following immune checkpoint inhibitors. Clinics and Research in Hepatology and Gastroenterology, 2023, 47 (8), pp.102203. ⟨10.1016/j.clinre.2023.102203⟩. ⟨hal-04205722⟩
47 Consultations
201 Téléchargements

Altmetric

Partager

  • More